Kenji Irie

This inventor holds 7 USPTO granted patents. Top assignees: Sumitomo Chemical Company, Limited, Sumitomo Pharmaceuticals Company Limited. Active years: 1977-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Irie. Retrieved from https://idiyas.com/inventor/kenji-irie-tlvhqza9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 122(Granted Patents)

Location History:

Takarazuka, JA (1977)
Takarazuka, JP (1978 - 1979)
Kawanishi, JP (1993)
Nishinomiya, JP (1997)

Company Filing History:

6 out of 6,965

Sumitomo Chemical Company, Limited

patents

2 out of 174

Sumitomo Pharmaceuticals Company Limited

patents

where one patent can have more than one assignee

Years Active: 1977-1997

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5646154 - Pharmaceutical compositions for inhibiting the formation of tumor (1997-07-08),

2. 5196337 - Human monoclonal antibody, and its production and use (1993-03-23),

3. 4160087 - N-acylamino-.alpha.-arylacetamido cephalosporins (1979-07-03),

4. 4156724 - N-acylamino-alpha-arylacetamido cephalosporins and antibacterial (1979-05-29),

5. 4117126 - 7-(.alpha.-(4-Hydroxy-1,5-naphthyridine-3-carbonamido)-.alpha.-ph (1978-09-26),

6. 4061748 - 7-(.alpha.-(4 (1977-12-06),

7. 4046904 - Novel penicillin, and its preparation and use (1977-09-06),

Title: Kenji Irie: Innovator in Pharmaceutical Research

Introduction

Kenji Irie is a prominent inventor based in Takarazuka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of monoclonal antibodies. With a total of seven patents to his name, Irie's work has had a profound impact on medical research and treatment.

Latest Patents

Among his latest patents, Irie has developed pharmaceutical compositions aimed at inhibiting tumor formation. One notable patent involves a human monoclonal antibody that has both prophylactic and therapeutic effects against infectious diseases caused by Pseudomonas aeruginosa. This antibody targets specific epitopes located in the O-antigen of serotypes A and H of the bacteria. Additionally, his patents include processes for producing hybridomas that generate these human monoclonal antibodies.

Career Highlights

Throughout his career, Kenji Irie has worked with esteemed organizations such as Sumitomo Chemical Company and Sumitomo Pharmaceuticals. His experience in these companies has allowed him to collaborate on groundbreaking research and development projects in the pharmaceutical industry.

Collaborations

Irie has collaborated with notable colleagues, including Hiroshi Noguchi and Hirotada Yamada. These partnerships have further enhanced his research capabilities and contributed to the advancement of innovative medical solutions.

Conclusion

Kenji Irie is a distinguished inventor whose work in pharmaceutical research continues to influence the medical field. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific advancements.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]